<p>安德鲁·希尔投资顾问公司在最近向美国证券交易委员会提交的 13F 文件中披露，在第四季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股增加了 79.6%。该公司在此期间额外购买了 6,044 股后，持有 13,634 股该生物技术公司的股票。联合治疗公司占安德鲁·希尔投资顾问公司投资组合的 3.6%，是其第 13 大持股。根据其最近向美国证券交易委员会提交的文件，安德鲁·希尔投资顾问公司在联合治疗公司的持股价值为 4,811,000 美元。</p>
<p>获取 <strong>联合治疗</strong> 的提醒：</p>
<ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
<p>其他一些对冲基金和机构投资者也调整了对该公司的持股。Milestone Asset Management LLC 在第四季度将其在联合治疗公司的持股增加了 56.5%。Milestone Asset Management LLC 现在持有 2,874 股该生物技术公司的股票，价值 1,014,000 美元，此前在此期间额外购买了 1,037 股。韩国投资公司在第四季度将其在联合治疗公司的持股增加了 6.2%。韩国投资公司现在持有 39,289 股该生物技术公司的股票，价值 13,863,000 美元，此前在此期间购买了 2,300 股。Janney Montgomery Scott LLC 在第四季度将其在联合治疗公司的持股增加了 9.1%。Janney Montgomery Scott LLC 现在持有 9,427 股该生物技术公司的股票，价值 3,326,000 美元，此前在此期间购买了 789 股。摩根大通在第三季度将其在联合治疗公司的持股增加了 35.4%。摩根大通现在持有 192,546 股该生物技术公司的股票，价值 68,999,000 美元，此前在上个季度购买了 50,291 股。最后，Burney Co.在第四季度将其在联合治疗公司的持股增加了 113.3%。Burney Co.现在持有 23,922 股该生物技术公司的股票，价值 8,441,000 美元，此前在上个季度购买了 12,705 股。目前 94.08% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>几位分析师对 UTHR 股票发布了报告。StockNews.com 在 2 月 27 日的报告中将联合治疗的评级从 “强力买入” 下调至 “买入”。瑞银集团在 1 月 8 日的研究报告中将联合治疗的目标价格从 415.00 美元上调至 475.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 2 月 27 日的报告中重申了 “买入” 评级，并设定了 425.00 美元的目标价格。一位股票研究分析师对该股票给予了卖出评级，两位给予了持有评级，十位给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 388.25 美元。</p>
<ul>
<li>分析师表示这两只中型生物技术股具有 2 倍潜力</li>
</ul>
<p><strong>阅读我们关于 UTHR 的最新股票报告</strong></p>
<h2>联合治疗股票上涨 4.7%</h2>
<p>联合治疗的股票在周四开盘价为 292.78 美元。该公司的 50 日简单移动平均线为 326.18 美元，200 日简单移动平均线为 352.23 美元。联合治疗公司的 52 周低点为 230.39 美元，52 周高点为 417.82 美元。该公司的市值为 131.5 亿美元，市盈率为 12.86，市盈增长比率为 0.97，贝塔值为 0.63。</p>
<p>联合治疗（NASDAQ:UTHR - 获取免费报告）最近在 2 月 26 日发布了季度财报。该生物技术公司报告本季度每股收益（EPS）为 6.19 美元，超出市场共识预期的 6.10 美元，超出 0.09 美元。该公司本季度的收入为 7.359 亿美元，而市场共识预期为 7.3474 亿美元。联合治疗的股本回报率为 19.22%，净利润率为 40.31%。在去年同期，该公司每股收益为 4.36 美元。分析师预计联合治疗公司本财年的每股收益将达到 24.48 美元。</p>
<h2>联合治疗的内部交易</h2>
<p>在相关消息中，董事雷蒙德·德维克在 4 月 7 日的交易中出售了 4,000 股公司的股票。该股票以 284.55 美元的平均价格出售，总交易额为 1,138,200.00 美元。交易后，该董事现在直接持有 1,750 股公司的股票，价值 497,962.50 美元。这笔交易代表了他们持股的 69.57% 的减少。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席运营官迈克尔·本科维茨在 1 月 21 日的交易中出售了 10,000 股公司的股票。该股票以 364.91 美元的平均价格出售，总价值为 3,649,100.00 美元。出售后，首席运营官现在持有 2,577 股公司的股票，价值约 940,373.07 美元。这笔交易代表了他们持股的 79.51% 的减少。该销售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 87,500 股公司股票，价值 30,640,680 美元。11.90% 的股票由公司内部人士持有。</p>
<h2>联合治疗公司简介</h2>
<p>（免费报告）</p>
<p>联合治疗公司是一家生物技术公司，致力于开发和商业化产品，以满足美国及国际上慢性和危及生命疾病患者的未满足医疗需求。该公司提供 Tyvaso DPI，一种通过预填充和一次性使用的药筒吸入的干粉；Tyvaso，一种通过超声雾化器吸入的溶液；Remodulin（特普瑞斯汀）注射液，用于治疗肺动脉高压（PAH）患者，以减轻与运动相关的症状；Orenitram，一种特普瑞斯汀的片剂，用于延缓疾病进展并改善 PAH 患者的运动能力；以及 Adcirca，一种口服 PDE-5 抑制剂，用于增强 PAH 患者的运动能力。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比联合治疗更好的股票</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>博通的强劲表现显示出关税下降中的韧性</li>
<li>什么是股息挑战者？</li>
<li>Carvana：能否在市场逆风中实现强劲反弹？</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Meta 在 FTC 审判中寻求特朗普的帮助：影响巨大</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在联合治疗吗？</h2>
<p>在你考虑联合治疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而联合治疗并不在名单上。</p>
<p>虽然联合治疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

联合治疗

<p>Andrew Hill Investment Advisors Inc. 在第四季度将其在联合治疗公司（NASDAQ:UTHR）的持股增加了 79.6%，目前持有 13,634 股，价值为 481 万美元。其他机构投资者也提高了他们的持仓。分析师对 UTHR 的评级不一，普遍评级为 “适度买入”，平均目标价为 388.25 美元。联合治疗公司的股票开盘价为 292.78 美元，市值为 131.5 亿美元，最近的每股收益为 6.19 美元，超出预期。内部交易中，董事 Raymond Dwek 进行了大规模的出售</p>

<p>Andrew Hill Investment Advisors Inc. grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 79.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,634 shares of the biotechnology company's stock after acquiring an additional 6,044 shares during the period. United Therapeutics comprises 3.6% of Andrew Hill Investment Advisors Inc.'s investment portfolio, making the stock its 13th biggest holding. Andrew Hill Investment Advisors Inc.'s holdings in United Therapeutics were worth $4,811,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>安德鲁·希尔投资顾问公司在最近向美国证券交易委员会提交的 13F 文件中披露，在第四季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股增加了 79.6%。该公司在此期间额外购买了 6,044 股后，持有 13,634 股该生物技术公司的股票。联合治疗公司占安德鲁·希尔投资顾问公司投资组合的 3.6%，是其第 13 大持股。根据其最近向美国证券交易委员会提交的文件，安德鲁·希尔投资顾问公司在联合治疗公司的持股价值为 4,811,000 美元。</p>
</div><p>Get <strong>United Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>联合治疗</strong> 的提醒：</p>
</div><ul>
<li>Liquidia: Court victory the awakening of an industry giant?</li>
</ul>
<div class="lb-trans"><ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also modified their holdings of the company. Milestone Asset Management LLC lifted its position in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 1,037 shares during the period. Korea Investment CORP raised its holdings in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares during the period. Janney Montgomery Scott LLC raised its position in United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after purchasing an additional 789 shares during the period. JPMorgan Chase &amp; Co. grew its stake in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Finally, Burney Co. raised its stake in United Therapeutics by 113.3% during the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock valued at $8,441,000 after buying an additional 12,705 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也调整了对该公司的持股。Milestone Asset Management LLC 在第四季度将其在联合治疗公司的持股增加了 56.5%。Milestone Asset Management LLC 现在持有 2,874 股该生物技术公司的股票，价值 1,014,000 美元，此前在此期间额外购买了 1,037 股。韩国投资公司在第四季度将其在联合治疗公司的持股增加了 6.2%。韩国投资公司现在持有 39,289 股该生物技术公司的股票，价值 13,863,000 美元，此前在此期间购买了 2,300 股。Janney Montgomery Scott LLC 在第四季度将其在联合治疗公司的持股增加了 9.1%。Janney Montgomery Scott LLC 现在持有 9,427 股该生物技术公司的股票，价值 3,326,000 美元，此前在此期间购买了 789 股。摩根大通在第三季度将其在联合治疗公司的持股增加了 35.4%。摩根大通现在持有 192,546 股该生物技术公司的股票，价值 68,999,000 美元，此前在上个季度购买了 50,291 股。最后，Burney Co.在第四季度将其在联合治疗公司的持股增加了 113.3%。Burney Co.现在持有 23,922 股该生物技术公司的股票，价值 8,441,000 美元，此前在上个季度购买了 12,705 股。目前 94.08% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several analysts have issued reports on UTHR shares. StockNews.com downgraded United Therapeutics from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $388.25.</p>
<div class="lb-trans"><p>几位分析师对 UTHR 股票发布了报告。StockNews.com 在 2 月 27 日的报告中将联合治疗的评级从 “强力买入” 下调至 “买入”。瑞银集团在 1 月 8 日的研究报告中将联合治疗的目标价格从 415.00 美元上调至 475.00 美元，并给予该股票 “买入” 评级。最后，HC Wainwright 在 2 月 27 日的报告中重申了 “买入” 评级，并设定了 425.00 美元的目标价格。一位股票研究分析师对该股票给予了卖出评级，两位给予了持有评级，十位给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 388.25 美元。</p>
</div><ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两只中型生物技术股具有 2 倍潜力</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on UTHR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 UTHR 的最新股票报告</strong></p>
</div><h2>United Therapeutics Stock Up 4.7 %</h2>
<div class="lb-trans"><h2>联合治疗股票上涨 4.7%</h2>
</div><p>Shares of United Therapeutics stock opened at $292.78 on Thursday. The business has a fifty day simple moving average of $326.18 and a 200-day simple moving average of $352.23. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.</p>
<div class="lb-trans"><p>联合治疗的股票在周四开盘价为 292.78 美元。该公司的 50 日简单移动平均线为 326.18 美元，200 日简单移动平均线为 352.23 美元。联合治疗公司的 52 周低点为 230.39 美元，52 周高点为 417.82 美元。该公司的市值为 131.5 亿美元，市盈率为 12.86，市盈增长比率为 0.97，贝塔值为 0.63。</p>
</div><p>United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company posted $4.36 EPS. Analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>联合治疗（NASDAQ:UTHR - 获取免费报告）最近在 2 月 26 日发布了季度财报。该生物技术公司报告本季度每股收益（EPS）为 6.19 美元，超出市场共识预期的 6.10 美元，超出 0.09 美元。该公司本季度的收入为 7.359 亿美元，而市场共识预期为 7.3474 亿美元。联合治疗的股本回报率为 19.22%，净利润率为 40.31%。在去年同期，该公司每股收益为 4.36 美元。分析师预计联合治疗公司本财年的每股收益将达到 24.48 美元。</p>
</div><h2>Insider Transactions at United Therapeutics</h2>
<div class="lb-trans"><h2>联合治疗的内部交易</h2>
</div><p>In related news, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the transaction, the director now directly owns 1,750 shares of the company's stock, valued at $497,962.50. This trade represents a 69.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 87,500 shares of company stock valued at $30,640,680. 11.90% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事雷蒙德·德维克在 4 月 7 日的交易中出售了 4,000 股公司的股票。该股票以 284.55 美元的平均价格出售，总交易额为 1,138,200.00 美元。交易后，该董事现在直接持有 1,750 股公司的股票，价值 497,962.50 美元。这笔交易代表了他们持股的 69.57% 的减少。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席运营官迈克尔·本科维茨在 1 月 21 日的交易中出售了 10,000 股公司的股票。该股票以 364.91 美元的平均价格出售，总价值为 3,649,100.00 美元。出售后，首席运营官现在持有 2,577 股公司的股票，价值约 940,373.07 美元。这笔交易代表了他们持股的 79.51% 的减少。该销售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 87,500 股公司股票，价值 30,640,680 美元。11.90% 的股票由公司内部人士持有。</p>
</div><h2>United Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>联合治疗公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.</p>
<div class="lb-trans"><p>联合治疗公司是一家生物技术公司，致力于开发和商业化产品，以满足美国及国际上慢性和危及生命疾病患者的未满足医疗需求。该公司提供 Tyvaso DPI，一种通过预填充和一次性使用的药筒吸入的干粉；Tyvaso，一种通过超声雾化器吸入的溶液；Remodulin（特普瑞斯汀）注射液，用于治疗肺动脉高压（PAH）患者，以减轻与运动相关的症状；Orenitram，一种特普瑞斯汀的片剂，用于延缓疾病进展并改善 PAH 患者的运动能力；以及 Adcirca，一种口服 PDE-5 抑制剂，用于增强 PAH 患者的运动能力。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than United Therapeutics</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Broadcom's Big Outperformance Shows Strength Amid Tariff Decline</li>
<li>What Are Dividend Challengers?</li>
<li>Carvana: Can Turnaround Strength Outdrive Market Headwinds?</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比联合治疗更好的股票</li>
<li>高股息 REIT：它们是理想的多元化方式吗？</li>
<li>博通的强劲表现显示出关税下降中的韧性</li>
<li>什么是股息挑战者？</li>
<li>Carvana：能否在市场逆风中实现强劲反弹？</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Meta 在 FTC 审判中寻求特朗普的帮助：影响巨大</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=UTHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in United Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在联合治疗吗？</h2>
</div><p>Before you consider United Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑联合治疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而联合治疗并不在名单上。</p>
</div><p>While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然联合治疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Andrew Hill Investment Advisors Inc. 购买了 United Therapeutics Co. (NASDAQ:UTHR) 的股份